Sodium AescinateCAS# 20977-05-3 |
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
| Cas No. | 20977-05-3 | SDF | Download SDF |
| PubChem ID | 3084345 | Appearance | Powder |
| Formula | C54H84NaO23 | M.Wt | 1124.2 |
| Type of Compound | Triterpenoids | Storage | Desiccate at -20°C |
| Solubility | ≥24.5mg/ml in DMSO | ||
| SMILES | CC(C(C)OC(=O)C)C(=O)OCC12C3CC(C(C1O)OC2CC4(C3=CCC5C4(CCC6C5(CCC(C6(C)CO)OC7C(C(C(C(O7)C(=O)O)OC8C(C(C(C(O8)CO)O)O)O)O)OC9C(C(C(CO9)O)O)O)C)C)C)(C)C.[Na+] | ||
| Standard InChIKey | OJTQULAMLNBGOY-RRKCPRGASA-N | ||
| Standard InChI | InChI=1S/C54H84O23.Na/c1-22(23(2)71-24(3)57)45(68)70-21-54-26-16-49(4,5)43(42(54)65)73-32(54)17-53(9)25(26)10-11-30-50(6)14-13-31(51(7,20-56)29(50)12-15-52(30,53)8)74-48-40(76-46-36(62)33(59)27(58)19-69-46)38(64)39(41(77-48)44(66)67)75-47-37(63)35(61)34(60)28(18-55)72-47;/h10,22-23,26-43,46-48,55-56,58-65H,11-21H2,1-9H3,(H,66,67);/q;+1/t22?,23?,26?,27-,28-,29?,30?,31?,32-,33+,34-,35+,36-,37-,38+,39+,40-,41+,42?,43-,46+,47-,48-,50?,51-,52?,53-,54?;/m1./s1 | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
| Description | 1. Sodium aescinate has anti-inflammatory and antioxidant activities, may effectively control and improve wound healing in diabetic rats. 2. Sodium aescinate can protect the lung injury induced by intestinal ischemia/reperfusion (I/R), which may be mediated by inhibiting lipid peroxidation, upregulating Bcl-2 gene protein expression, improving the ratio of Bcl-2/ Bax to inhibit lung apoptosis. 3. Sodium aescinate has obvious antiangiogenic effect, the initiation of angiogenesis and proliferation of endothelial cell are inhibited and the secretion of VEGF is also decreased. 4. Sodium aescinate has immunity enhancing and antioxidative effects, sodium aescinate injection liquid can decrease oxidative injury and enhance immunity functions in hepatocellular carcinoma (HCC) mice. 5. Sodium aescinate can protect against liver injury induced by methyl parathion and that the mechanism of action is related to its antioxidative and anti-inflammatory effects. |
| Targets | NO | TNF-α | IL Receptor | Bcl-2/Bax | VEGFR |
Sodium Aescinate Dilution Calculator
Sodium Aescinate Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 0.8895 mL | 4.4476 mL | 8.8952 mL | 17.7904 mL | 22.238 mL |
| 5 mM | 0.1779 mL | 0.8895 mL | 1.779 mL | 3.5581 mL | 4.4476 mL |
| 10 mM | 0.089 mL | 0.4448 mL | 0.8895 mL | 1.779 mL | 2.2238 mL |
| 50 mM | 0.0178 mL | 0.089 mL | 0.1779 mL | 0.3558 mL | 0.4448 mL |
| 100 mM | 0.0089 mL | 0.0445 mL | 0.089 mL | 0.1779 mL | 0.2224 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- CART (55-102) (rat)
Catalog No.:BCC6006
CAS No.:209615-79-2
- Dihydroisotanshinone I
Catalog No.:BCN2308
CAS No.:20958-18-3
- Isotanshinone I
Catalog No.:BCN2500
CAS No.:20958-17-2
- Isotanshinone IIA
Catalog No.:BCN2501
CAS No.:20958-15-0
- SB 271046 hydrochloride
Catalog No.:BCC1924
CAS No.:209481-24-3
- SB271046
Catalog No.:BCC5057
CAS No.:209481-20-9
- 1-(2-Amino-5-chlorophenyl)-1-(trifluoromethyl)-3-cyclopropyl-2-propyn-1-ol
Catalog No.:BCC8404
CAS No.:209414-27-7
- VX-745
Catalog No.:BCC3966
CAS No.:209410-46-8
- Platycoside A
Catalog No.:BCN3241
CAS No.:209404-00-2
- Beta-mangostin
Catalog No.:BCN1213
CAS No.:20931-37-7
- Neocryptomerin
Catalog No.:BCN8023
CAS No.:20931-36-6
- Fmoc- ß-HoAsp(OtBu)-OH
Catalog No.:BCC3230
CAS No.:209252-17-5
- Entinostat (MS-275,SNDX-275)
Catalog No.:BCC3595
CAS No.:209783-80-2
- AR-M 1000390 hydrochloride
Catalog No.:BCC6143
CAS No.:209808-47-9
- Tafluprost
Catalog No.:BCC5270
CAS No.:209860-87-7
- Resibufagin
Catalog No.:BCN8230
CAS No.:20987-24-0
- H-Phenylglycinol
Catalog No.:BCC2713
CAS No.:20989-17-7
- Androst-5-ene-3β,17β-diol 3,17-diacetate
Catalog No.:BCC8823
CAS No.:2099-26-5
- YO-01027 (Dibenzazepine, DBZ)
Catalog No.:BCC2100
CAS No.:209984-56-5
- LY-411575
Catalog No.:BCC2101
CAS No.:209984-57-6
- LY-411575 isomer 1
Catalog No.:BCC5443
CAS No.:209984-58-7
- LY-900009
Catalog No.:BCC2103
CAS No.:209984-68-9
- Erythbidin A
Catalog No.:BCN6859
CAS No.:210050-83-2
- Nilgirine
Catalog No.:BCN2100
CAS No.:21009-05-2
Sodium aescinate ameliorates liver injury induced by methyl parathion in rats.[Pubmed:22969975]
Exp Ther Med. 2012 May;3(5):818-822.
Methyl parathion, a highly cytotoxic insecticide, has been used in agricultural pest control for several years. The present study investigated the protective effect of Sodium Aescinate (SA, the sodium salt of aescin) against liver injury induced by methyl parathion. Forty male Sprague-Dawley rats were randomly divided into 5 groups of 8 animals: the control group; the methyl parathion (15 mg/kg) poisoning (MP) group; and the MP plus SA at doses of 0.45, 0.9 and 1.8 mg/kg groups. Alanine aminotransferase (ALT), aspartate aminotransferase (AST) and acetylcholinesterase (AChE) in the plasma were assayed. Nitric oxide (NO) and antioxidative parameters were measured. Histopathological examination of the liver was also performed. The results revealed that SA had no effect on AChE. Treatment with SA decreased the activities of ALT and AST, and the levels of malondialdehyde and NO. Treatment with SA also increased the level of glutathione and the activities of superoxide dismutase and glutathione peroxidase. SA administration also ameliorated liver injury induced by methyl parathion poisoning. The findings indicate that SA protects against liver injury induced by methyl parathion and that the mechanism of action is related to the antioxidative and anti-inflammatory effects of SA.
[Effects of sodium aescinate on the apoptosis-related genes in lung injury induced by intestinal ischemia reperfusion in rats].[Pubmed:22650024]
Sichuan Da Xue Xue Bao Yi Xue Ban. 2012 Mar;43(2):170-3.
OBJECTIVE: To investigate the relationship between apoptosis-related genes and lung injury induced by intestinal ischemia reperfusion and to explore the effects and its possible mechanism of Sodium Aescinate. METHODS: Rat model of intestinal I/R injury was established with clamping of the superior mesenteric artery for 60 min and then clamping was relieved for 60 min. Twenty-four SD rats were randomly divided into three groups with eight rats in each: sham group, intestinal ischemia/reperfusion group (I/R group) and Sodium Aescinate group (SA + I/R group). Lung wet/dry weight ratio, lung coefficient and Superoxide dismutase (SOD), malondialdehyde (MDA) in plasma and lung tissue were measured, as well as the expression levels of Bcl-2 and Bax proteins in lung tissue were examined using immunohistochemical method. RESULTS: Compared with sham group, lung wet/dry weight ratio, lung coefficient and MDA in plasma and lung tissue were significantly increased, and while the activity of SOD in plasma and lung tissue were decreased significantly in I/R group. At the same time, the protein expression level of Bcl-2 and Bax were significantly increased. But Bax protein expression was much greater than that of Bcl-2, the ratio of Bcl-2 to Bax was decreased significantly in I/R group than that in sham group. Compared with I/R group, lung wet/dry weight ratio, lung coefficient and MDA in plasma and lung tissue were significantly decreased, and while the activity of SOD in serum and lung tissue were significantly increased in SA + I/R group. At the same time, Bax protein expression was significantly decreased, both Bcl-2 protein expression and the ratio of Bcl-2 to Bax were significantly increased in SA + I/R group than that in I/R group. CONCLUSION: Lung injury induced by intestinal ischemia reperfusion is correlated with abnormal expression levels of Bcl-2 and Bax protein which is caused by oxidative injury. Sodium Aescinate can protect the lung injury induced by intestinal ischemia/reperfusion (I/R), which may be mediated by inhibiting lipid peroxidation, upregulating Bcl-2 gene protein expression, improving the ratio of Bcl-2/ Bax to inhibit lung apoptosis.
Evaluation of in vivo antioxidant and immunity enhancing activities of sodium aescinate injection liquid.[Pubmed:22926307]
Molecules. 2012 Aug 27;17(9):10267-75.
Oxidative stress is involved in the development and progression of disease. Because Sodium Aescinate has been reported to have immunity enhancing and antioxidative effects, we investigated its activity by employing a hepatocellular carcinoma (HCC) mouse model. Sixty BALB/c mice were randomly divided into four groups, including a 1.4 mg/kg treated group (n = 15), a 2.8 mg/kg treated group (n = 15), an untreated hepatocellular carcinoma control group (n = 15) and a normal control group (n = 15). After H22 cells were cultured for one week, we collected 2 x 10(6) cells and injected them subcutaneously as 0.2 mL cell suspensions in sterile saline into the right shoulder region of every mouse. The animals were monitored for changes in activity, physical condition and body weight during the experiment. The next day after injection of H22 cells, animals in these test groups received one intraperitoneal injection of drug or physiological saline for 13 days. Results showed that in the Sodium Aescinate injection liquid (SAIL)-treated HCC mice, serum interleukin-1 beta (IL-1beta), interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-alpha), interferon-gamma (IFN-gamma), Gamma-glutamyltransferase (gamma-GT), alanine transaminase (ALT), aspartate transaminase (AST) and alkaline phosphatase (ALP) levels were significantly decreased compared with normal control mice. In addition, treatment with Sodium Aescinate injection liquid significantly decreased blood and liver malondialdehyde (MDA) levels, increased glutathione (GSH) levels, and antioxidant enzyme [superoxide dismutase (SOD), catalase (CAT) and glutathione peroxidase (GSH-Px)] activities in a dose-dependent manner. We conclude that Sodium Aescinate injection liquid can decrease oxidative injury and enhance immunity functions in HCC mice.
The Efficacy of Sodium Aescinate on Cutaneous Wound Healing in Diabetic Rats.[Pubmed:25903967]
Inflammation. 2015 Oct;38(5):1942-8.
This study is aimed to evaluate the potential effects of Sodium Aescinate (SA, the sodium salt of aescin) on wound healing in streptozotocin-induced diabetic rats. An excision skin wound was created in diabetic rats, and the wounded rats were divided into three groups: I) control group, II) gel-treated group, and III) SA-treated group. The control group wounds received topically normal saline once daily for 19 days. The gel-treated and SA-treated wounds received topically 400 mul of pluronic F-127 gel (25%) and 400 mul of SA (0.3%) in pluronic gel, respectively, once daily for 19 days. SA application in diabetic rats increased the wound contraction and significantly decreased the level of the inflammatory cytokine tumor necrosis factor-alpha (TNF-alpha) in comparison to the gel-treated group and control group. SA application in diabetic rats also resulted in a marked increase in the level of anti-inflammatory cytokine interleukin-10 (IL-10) and activities of antioxidant enzymes superoxide dismutase (SOD), catalase (CAT), and glutathione peroxidase (GSH-Px) compared to the other groups. Histopathologically, SA-treated wounds showed better granulation tissue dominated by marked fibroblast proliferation, and wounds were covered by thick regenerated epithelial layer. Additionally, the application of only pluronic gel produced some beneficial effects in some parameters in comparison to control group, but most of them were not significantly different. These findings demonstrated that SA may effectively control and improve wound healing in diabetic rats via its anti-inflammatory and antioxidant activities.
